Attached files
| file | filename |
|---|---|
| EX-31.2 - CERTIFICATION - Sunshine Biopharma, Inc | sbfm_ex3102.htm |
| EX-31.1 - CERTIFICATION - Sunshine Biopharma, Inc | sbfm_ex3101.htm |
| 10-Q - FORM 10-Q - Sunshine Biopharma, Inc | sbfm_i10q-20210630.htm |
Exhibit 32
CERTIFICATION PURSUANT TO
18 USC, SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with this quarterly report of Sunshine Biopharma, Inc. (the “Company”) on Form 10-Q for the six month period ended June 30, 2021, as filed with the Securities and Exchange Commission on August 9, 2021 (the “Report”), we, the undersigned, in the capacities and on the date indicated below, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:
| 1. | The Report fully complies with the requirements of Rule 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Dated: August 9, 2021 |
/s/ Dr. Steve N. Slilaty Dr. Steve N. Slilaty, Chief Executive Officer |
| Dated: August 9, 2021 |
/s/ Camille Sebaaly Camille Sebaaly, Chief Financial Officer |